Generated by AI
Kazia Therapeutics Ltd Sponsored ADR is a clinical-stage biotechnology company focused on oncology drug development. The company’s current programs center on investigational cancer therapies, including paxalisib, a brain-penetrant small-molecule candidate being developed for hard-to-treat brain tumors, and EVT801, a selective inhibitor targeting pathways involved in tumor growth and angiogenesis. Kazia Therapeutics also advances other research-stage assets aimed at addressing unmet needs in cancer treatment. Its work spans pharmaceutical discovery, preclinical research, and clinical development, with a particular emphasis on brain cancer and other aggressive solid tumors. As an ADR structure, it provides U.S. market access to an Australian-based biotechnology company whose business is concentrated on experimental therapeutics rather than commercialized products.
WebsiteThree International Towers
Sydney, NSW, 2000
Australia
The latest articles about KZIA.
Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, has been named "Drug Discovery Company of the Year" in the 2026 BioTech Breakthrough Awards program, recognizing the Company's innovative approach to developing next-generation cancer therapeutics.
Summary of Oct 14's posts. Generated by AI.
Summary of Aug 27's posts. Generated by AI.
Summary of Aug 27's posts. Generated by AI.
Investors talking about KZIA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.